Arch Biopartners Inc V.ARCH

Alternate Symbol(s): ACHFF

Technology Scientific & Technical Instruments

Arch Biopartners Inc. is a late-stage clinical trial company focused on preventing acute kidney injury. The Company is developing a platform of new drugs to prevent inflammation injury in the kidneys, lungs and liver via the dipeptidase-1 (DPEP1) pathway and are relevant for many common injuries and diseases where organ inflammation is an unmet problem. The Company’s lead drug candidate is LSALT Peptide. The Company is engaged in the clinical development of LSALT Peptide and other DPEP-1 targeting drug candidates for indications where inflammation of the lungs, liver and kidneys is an unmet problem. LSALT Peptide is in a second phase II trial, targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). The Company has additional technology platforms in its portfolio, which are AB569 and Borg. AB569 is an anti-infective candidate for treating or preventing antibiotic resistant bacterial infections, primarily as a topical treatment for wounds.

TSXV:ARCH - Post by User

Arch Biopartners Inc > Post Covid Potential of 5-15 billion annual Revenue

<< Previous

Bullboard Posts

Next >>

Comment by 2019champson Feb 14, 2021 5:27pm

99 Views

Post# 32565802

RE:Post Covid Potential of 5-15 billion annual Revenue

The kidney is 5 billion with no competition. Then you have the lung and the liver. Lets be extremely generous here and say this drug is worth 2B. That puts as at $30 share price. Again that is being extremely generous.

<< Previous

Bullboard Posts

Next >>

Who, why, and what of the great "Crypto Surge"